Writing in another group The New England Journal of Medicine Earlier this month, the trajectory of the virus was expanded in a 45-year-old man with an autoimmune disorder for which he was receiving immunosuppressants. In this case they found that the person had “rapid” growth of the virus, and Multiple mutations Spikes were in proteins. Most immunologists clarified SARS-CoV-2 infection without major complications, he wrote, “but this case highlights the possibility of persistent infection and hastens viral growth associated with an immunological state.”
The same situation has been observed in other situations where the immune system is obstructed. HIV attacks immune function, which allows it to develop at a surprisingly high rate, making it difficult for the body to continue to produce antibodies and neutralize the virus. By the same mechanism, HIV infection allows a longer period of time to morph and morph into other viruses in the individual. Herpes simplex virus may develop abnormal drug-resistance in patients with AIDS, for example.
Nonetheless, we really need a better understanding of which immunomompromised patients are vulnerable to long-lasting SARS-CoV-2 infection. The category of “immunocompromised” captures a wide range of different conditions, and not all of them can consistently pose the same risk as Kovid-19. Brian Wasick, a virologist at Cornell University, points out that the term may include people born with a rare disorder that impairs their ability to fight pathogens, as well as people who are taking immunosuppressants as a transgender or a Autoimmune can reduce disease.
Evidence for the relationship between immuno-compromised individuals and persistent SARS-CoV-2 infections and persistent infections and viral development is compelling enough to be considered in discussions of vaccine preference. On Sunday, a panel from the US Center for Disease Control and Prevention recommended That immunocompromised people are placed In “Phase 1C” – the third wave-vaccine rollout. This means that they are having cancer, coronary heart disease, or obesity along with other conditions to receive injections at the same time. The decision was made by Kovid-19 to address a particular risk for people with immune system issues, but left the possibility that vaccination of these individuals could help prevent the development of new SARS-CoV-2 variants Which will make this epidemic worse than before. For this reason, even though there are a handful of directly related case reports, public health officials should consult virologists about whether it might be wise to transfer immunologists to the first phase 1B group.
At the very least, we need better monitoring of potential changes in SARS-CoV-2. The US government should do more to help organize viral sequencing efforts. CDC has a program nickname Regions That has tried to capture sequence data during the epidemic, but it is falling short: where Britain has made a guess 10 percent of its Kovid-19 cases, America has only succeeded 0.3 percent. “It’s a bit patchy,” says Adam Loring of Michigan Medical School, who says his team uploaded about 2 percent of the sequence version data in the US. “The nation has vast swaths on the task where those people are not Who are spending a lot of time and effort “. Better monitoring of viral evolution may also clarify the question of where exactly sick people are most likely to accumulate these changes.
As we monitor for SARS-CoV-2 mutations, we must acknowledge that further work is needed to understand their epidemiological and clinical significance. Meanwhile, the virus is still prevalent, providing more opportunities for it to spread, even spreading from one person to another. But long-lasting infections in some immunological individuals, and the associated potential for viral development, should be the focus of attention.
More on Kovid-19